Phaseline

Targets › NNRTI

NNRTI: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease.

Open in Phaseline: the race on NNRTI, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Professor Francois VenterDelstrigo (DOR/3TC/TDF)
Non-nucleoside reverse transcriptase inhibitor (doravirine) with nucleoside reverse transc
INSTI, NNRTIPhase 3HIV-1-infection–

Conditions

HIV-1-infection (1)

Modalities

small molecule (1)

Companies

Professor Francois Venter (1)

Related targets

INSTI (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.